The National AIDS Treatment Advocacy Project - NATAP - provides the latest in HIV and AIDS drug research and treatment information as well as comprehensive reports and developments from the Fifth Retroviruses and Opportunistic Infections conference, as well as from the ICAR, ICAAC, IDSA, European and International HIV and AIDS conferences, and from other sources. 

• Jules Levin Reports Live from the American Association for the Study of Liver Diseases  51th Annual Meeting, Dallas, 
  Texas (11/1/2000)

• Selected Reports from the 5th International Congress on Drug Therapy in HIV Infection in Glasgow, Scotland (10/23/2000)

• Selected Reports from The ICAAC Conference in Toronto (9/20/2000)

• Selected Reports from The Lipodystrophy Workshop in Toronto: 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV  (8/15/2000)

• Selected Reports from the Durban World AIDS Conference 2000, Durban, South Africa  (7/28/2000)

• 4th International Workshop on HIV Drug Resistance and Treatment Strategies, Written by Jules Levin, Sitges, Spain, June 12-16 2000 (6/12/2000)

• Selected Reports from The DDW (Digestive Disease Week) Conference, San Diego, California, May 21-24, 2000 (5/23/2000)

• Selected Reports from The EASL Conference; European Association for the Study of the Liver, Rotterdam, April 28-May 3 (5/19/2000)

• Reports from The Third International Workshop on Salvage Therapy for HIV Infection; Chicago, April 12-14, 2000; (4/17/2000)

View these reports as slides in PDF format:

• 72 Week Update of 006 study:
  Efavirenz + AZT/3TC, Cal Cohen, MD, Lisbon 
  
  
• Efavirenz Pharmacokinetics;
  Therapeutic Drug Monitoring; ABT-378/r PK, Dr. David Back, University of Liverpool
  
  
• The tolerability and pharmacokinetics of saquinavir-SGC (FORTOVASE ^Æ; FTV) when administered in a once-a-day regimen with a mini dose of Ritonavir (RTV)
  
  
• Pharmacokinetic (PK) Interaction between the HIV Protease Inhibitors Tipranavir & Ritonavir
  

• NATAP at the 7th Conference on Retroviruses and Opportunistic Infections (HRC) in San Francisco
  
  

• Selected Highlights and Reports from Leading Researchers * (2/2/2000)
  
  

• National Institute of Allergy and Infectious Diseases Meeting:
  "Long-Term Studies in HIV-1 Infection Workshop" (1/17/2000)

 
IDSA, Infectious Disease Society of America,
Philadelphia
November 21, 2000

Report from IDSA: Structured Therapy Interruption